Delhi High Court imposed Rs 400 cap on rapid testing kits from China

NEW DELHI: Delhi high court capped the price of 4.5 lakh Covid-19 rapid testing kits that are likely to be delievered by China at Rs 400 each.
Justice Waziri’s order came on a petition and dispute between the two private firms by Rare Metabolics Life Sciences and Aark Pharmaceuticals, which had entered into a pact with Matrix Labs, their importer from China, to distribute them at Rs 600 each, the rate fixed by ICMR.

“The court is of the view that a profit mark-up of Rs 155, i.e. 61%, on the landed cost price of Rs 245 is much on the higher side and in any case more than sufficient for the seller, for the kit and tests to be made available in India for urgent extensive tests through the country, especially in these present extraordinary circumstances of the worldwide pandemic.” Justice Najmi Waziri said.

An official source also added that the kits had been procured by ICMR at short notice as there are very limited suppliers of kits in the market and the major source apart from local suppliers is China. The efforts to track other suppliers resulted in the discovery that the original makers were Chinese. A South Korean firm has also set up a partnership for manufacturing the kits in Manesar. ICMR is now checking the quality of the Chinese kits.
The court said, “For people to be assured that the pandemic is under control and for governments to ensure and for agencies engaged in the frontline battle to safeguard people’s health, more kits and tests should be made available urgently at the lowest cost… Public interest must outweigh private gain.”

According to the petition, the initial order was for nearly 10 lakh kits, of which 5 lakh were meant for ICMR and 2.76 lakh had already been delivered. However, Matrix Labs insisted that it would not hand over the remaining 2.24 lakh kits till it received full payment. The distributor companies told the court that as per the agreement, an initial payment of Rs 12.75 crore was made for import of 5 lakh test kits at Rs 600 each and the remaining Rs 8.25 crore was to be paid after it received money from ICMR.

  • Related Posts

    Glenmark Pharma’s US arm launches Latanoprost’s bioequivalent solution

    Glenmark Pharmaceuticals said that US-based Glenmark Pharmaceuticals Inc. has launched Latanoprost Ophthalmic Solution. The aforementioned solution is bioequivalent and therapeutically equivalent to the reference listed drug Xalatan Ophthalmic Solution of…

    HC denies bail to pharma company owner for manufacturing spurious drugs

    Shimla:  The Himachal Pradesh high court on Monday declined bail to the owner of pharmaceutical company M/s Glenmars Healthcare in the Baddi area of Solan district, from where a huge…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Eye stroke alert: Ozempic linked to rare vision-loss condition

    Eye stroke alert: Ozempic linked to rare vision-loss condition

    Glenmark to launch cancer drug Zanubrutinib in India

    Glenmark to launch cancer drug Zanubrutinib in India

    Drug smuggling racket busted inside Ropar jail; ASI, head constable, among others arrested

    Drug smuggling racket busted inside Ropar jail; ASI, head constable, among others arrested

    Nepal ex-PM under fire for alleged corruption over Patanjali-linked land deal, fined $1 million

    Nepal ex-PM under fire for alleged corruption over Patanjali-linked land deal, fined $1 million